Caliber Associates Recruits General Counsel for INOVIO Pharmaceuticals

Caliber Associates recently placed Michael Cordera as the new executive vice president and general counsel of INOVIO Pharmaceuticals. Steve Hochberg, CEO and founder of Caliber Associates, led the assignment. Mr. Cordera will serve on the company’s executive leadership team and will report to INOVIO’s president and CEO, J. Joseph Kim. In this role, he will be responsible for the company’s legal team and strategy. “Michael is a seasoned legal executive with deep life-sciences experience both in the U.S. and abroad,” said Dr. Kim. “His expertise surrounding commercial operations and global business development come at a key time for our organization. He will be a valuable leader as INOVIO executes on its plans to develop and commercialize DNA medicines to treat infectious diseases, cancer, and HPV-associated diseases.”

Mr. Cordera joins INOVIO from Eagle Pharmaceuticals, where he served as general counsel and chief compliance officer. Before Eagle, he held various legal positions of increasing responsibility at Warner Chilcot and inVentiv (now Syneos) Health where he was responsible for legal affairs in North America, Europe and Asia. Mr. Cordera began his legal career as an associate at Sherman & Sterling LLP.

INOVIO Pharmaceuticals is a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer. INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with COVID-19 and MERS, for which programs are being developed with funding support from the U.S. Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI).